Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Bw B 1090u
2. Bw B1090u
3. Bw-b 1090u
4. Bw-b-1090u
5. Bw-b1090u
6. Bwb 1090u
7. Bwb1090u
8. Mivacron
9. Mivacurium Chloride
1. Mivacurium Cation
2. Mivacurium Chloride
3. Mivacron
4. Bw-b109ou
5. 133814-19-4
6. Bw B109ou
7. Bis[3-[(1r)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propyl] (e)-oct-4-enedioate
8. 106791-40-6
9. Chebi:6958
10. Bwb109ou
11. (1r)-2-(3-{[(4e)-8-{3-[(1r)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propoxy}-8-oxooct-4-enoyl]oxy}propyl)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium
12. Ncgc00167469-01
13. Mivacurium Ion
14. Unii-77d66s9q93
15. Ncgc00183094-01
16. Dsstox_cid_28308
17. Dsstox_rid_82751
18. Dsstox_gsid_48333
19. Gtpl7243
20. Chembl1182833
21. Dtxsid6048333
22. Schembl10014476
23. Schembl10666872
24. Tox21_112909
25. 77d66s9q93
26. Db01226
27. Ncgc00167469-02
28. Cas-133814-19-4
29. C07550
30. 791m406
31. Q413877
32. Isoquinolinium, 2,2'-((1,8-dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl))bis(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)methyl)-, (1r-(1r*(e(1'r*))))-
| Molecular Weight | 1029.3 g/mol |
|---|---|
| Molecular Formula | C58H80N2O14+2 |
| XLogP3 | 8.7 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 30 |
| Exact Mass | 1028.56095523 g/mol |
| Monoisotopic Mass | 1028.56095523 g/mol |
| Topological Polar Surface Area | 145 Ų |
| Heavy Atom Count | 74 |
| Formal Charge | 2 |
| Complexity | 1550 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
FDA Label
Mivacurium is a short-acting, nondepolarizing skeletal neuromuscular blocking agent which is hydrolyzed by plasma cholinesterase. Mivacurium results in a blockade of neuromuscular transmission by binding competitively with cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine. The neuromuscular block produced by mivacurium is readily antagonized by anticholinesterase agents. The deeper the level of neuromuscular block at reversal, the longer the time required for recovery of neuromuscular function and the greater the dose of anticholinesterase agent required. Because spontaneous recovery after mivacurium is rapid, routine reversal may not always result in a clinical benefit.
Neuromuscular Nondepolarizing Agents
Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)
M - Musculo-skeletal system
M03 - Muscle relaxants
M03A - Muscle relaxants, peripherally acting agents
M03AC - Other quaternary ammonium compounds
M03AC10 - Mivacurium chloride
Extensive and rapid via enzymatic hydrolysis catalyzed by plasma cholinesterase. Biotransformation may be significantly slowed in patients with abnormal or decreased plasma cholinesterase activity, especially individuals with a homozygous atypical cholinesterase gene abnormality.
The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.
Mivacurium binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
ABOUT THIS PAGE
42
PharmaCompass offers a list of Mivacurium Cation API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Mivacurium Cation manufacturer or Mivacurium Cation supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Mivacurium Cation manufacturer or Mivacurium Cation supplier.
PharmaCompass also assists you with knowing the Mivacurium Cation API Price utilized in the formulation of products. Mivacurium Cation API Price is not always fixed or binding as the Mivacurium Cation Price is obtained through a variety of data sources. The Mivacurium Cation Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Mivacurium Cation manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mivacurium Cation, including repackagers and relabelers. The FDA regulates Mivacurium Cation manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mivacurium Cation API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Mivacurium Cation supplier is an individual or a company that provides Mivacurium Cation active pharmaceutical ingredient (API) or Mivacurium Cation finished formulations upon request. The Mivacurium Cation suppliers may include Mivacurium Cation API manufacturers, exporters, distributors and traders.
Mivacurium Cation Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mivacurium Cation GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mivacurium Cation GMP manufacturer or Mivacurium Cation GMP API supplier for your needs.
A Mivacurium Cation CoA (Certificate of Analysis) is a formal document that attests to Mivacurium Cation's compliance with Mivacurium Cation specifications and serves as a tool for batch-level quality control.
Mivacurium Cation CoA mostly includes findings from lab analyses of a specific batch. For each Mivacurium Cation CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mivacurium Cation may be tested according to a variety of international standards, such as European Pharmacopoeia (Mivacurium Cation EP), Mivacurium Cation JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mivacurium Cation USP).
